FRANKFURT (dpa-AFX Broker) - Deutsche Bank Research has lowered the target price for Schott Pharma from 45 to 35 euros after a profit warning, but left the rating at "Buy". The medium-term outlook remains good, wrote analyst Falko Friedrichs in his reaction to the "first crack" in the investment story on Tuesday. The pharmaceutical glass specialist remains a high-quality growth company in an attractive industry./ag/tih

Publication of the original study: 21.05.2024 / time not specified in study / CEST

First dissemination of the original study: 21/05/2024 / 08:10 / CEST

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------